General Pharmacology
The Vascular System

Volumes 36–37

Numbers 1–12

January–December 2001

Cumulative Author and Subject Index for Volumes 1 to 35

Editor In Chief
John D. Catravas
Medical College of Georgia

Associate Editors
Napoleone Ferrara
Genentech, Inc.

Victor W. M. van Hinsbergh
Gaubius Laboratory TNO-PG

A. Jake Lusis
UCLA

Alberto Nasjletti
New York Medical College

William C. Sessa
Yale Univesity School of Medicine

http://www.elsevier.com/locate/genpharm
http://www.mcg.edu/centers/vbc

ISSN 0306-3623

ELSEVIER

General Pharmacology
The Vascular System

Editor-in-Chief
John D. Catravas
Vascular Biology Center
Medical College of Georgia
Augusta, GA 30912-2510
Telephone: (706) 721 6338
Fax: (706) 721 9799
E-mail: jcatrava@mail.mcg.edu

Associate Editors

ANGIOGENESIS/GROWTH FACTORS
Napoleone Ferrara
Genentech, Inc.

NITRIC OXIDE/CELL SIGNALLING
William C. Sessa
Yale University

BLOOD ELEMENT-VESSEL WALL INTERACTIONS
Victor W. M. van Hinsbergh
Gaubius Laboratory TNO-PG

ATHEROSCLEROSIS/METABOLIC DISEASES
A. Jake Lusis
UCLA

Editorial Board

Alan D. Attie
Madison, WI

Carole L. Banka
La Jolla, CA

William H. Beierwaltes
Detroit, MI

Bradford C. Berk
Rochester, NY

Judith A. Berliner
Los Angeles, CA

Chantal M. Boulanger
Paris, France

Rudi Busse
Frankfurt, Germany

William B. Campbell
Milwaukee, WI

Gerald O. Carrier
Augusta, GA

Adrian Chester
Middlesex, UK

Giuseppe Cirino
Naples, Italy

Richard A. Cohen
Boston, MA

Pedro D'Orleans-Juste
Quebec, Canada

Debra I. Diz
Winston-Salem, NC

Thomas S. Edgington
La Jolla, CA

Gregory D. Fink
East Lansing, MI

John A. Frangos
La Jolla, CA

Bruce Freeman
Birmingham, AL

Haralambos Gavras
Boston, MA

Steven S. Gross
New York, NY

Aviv Hassid
Memphis, TN

Donald D. Heistad
Iowa City, IA

Timothy Hla
Farmington, CT

George L. King
Boston, MA

Alisa E. Koch
Chicago, IL

Brian R. Krauss
Ann Arbor, MI

Ronald M. Krauss
Berkeley, CA

Thomas F. Luscher
Zurich, Switzerland

Kevin R. Lynch
Charlottesville, VA

Kafait U. Malik
Memphis, TN

Michael E. Maragoudakis
Patras, Greece

Harry S. Margolius
Charleston, SC

Salvador Moncada
London, UK

Ferid Murad
Houston, TX

Suzanne Oparil
Birmingham, AL

Sampath Parthasarathy
Atlanta, GA

Bruce R. Pitt
Pittsburgh, PA

Jennifer S. Pollock
Augusta, GA

Lyn Powell-Braxton
South San Francisco, CA

Russell L. Prewitt
Norfolk, VA

Mohan K. Raizada
Gainesville, FL

Kenneth Ramos
College Station, TX

Robert A. Roth
East Lansing, MI

Nancy J. Rusch
Milwaukee, WI

Una S. Ryan
Needham, MA

Jan E. Schnitzer
Boston, MA

Curt D. Sigmund
Iowa City, IA

Michael Simons
Boston, MA

Pieter B.M.W.M. Timmermans
South San Francisco, CA

Richard C. Venema
Augusta, GA

Devendra Vora
Los Angeles, CA

Timothy D. Warner
London, UK

R. Clinton Webb
Ann Arbor, MI

Stephen J. Weiss
Ann Arbor, MI

General Pharmacology
The Vascular System

Volumes 36–37

Numbers 1–12

January–December 2001

Contents

Cumulative Author and Subject Index for Volumes 1 to 35

Publisher's Note v

Author Index Volumes 1–35 1

Subject Index Volumes 1–35 207

General Pharmacology
The Vascular System

Aims and Scope

General Pharmacology publishes papers, written in English, which contain results of all aspects of the pharmacology of *The Vascular System*.

Papers are encouraged in all areas, including angiogenesis, growth factors, nitric oxide, cell signalling, vasoactive mediators, hypertension, atherosclerosis, metabolic diseases, blood element-vessel wall interactions, thrombosis, microcirculation, vascular developmental biology and remodeling, vascular inflammation and immunity. Papers are encouraged on pharmacologial research utilizing approaches ranging from molecular biology to integrative physiology.

The journal publishes invited reviews, rapid communications and regular research articles. Sponsored supplements and special issues of collections of papers on the same subject are also published, and can be arranged through negotiation with the Editor.

© 2002 Elsevier Science Inc. All rights reserved.

This journal and the individual contributions contained in it are protected under copyright by Elsevier Science Inc. and the following terms and conditions apply to their use:

Photocopying. Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Permissions may be sought directly from Elsevier Science Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; phone (+44) 1865 843830, fax: (+44) 1865 853333, e-mail: permissions@elsevier.co.uk. You may also contact Rights & Permissions directly through Elsevier's home page (http://www.elsevier.com), selecting first 'Customer Support', then 'General Information', then 'Permissions Query Form'.

In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (978) 750 8400, fax: (978) 750 4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone (+44) 171 436 5931; fax: (+44) 171 436 3986. Other countries may have a local reprographic rights agency for payments.

Derivative Works. Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution.

Permission of the publisher is required for all other derivative works, including compilations and translations.

Electronic Storage or Usage. Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated.

Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher.

Address permissions requests to: Elsevier Science Rights & Permissions Department, at the mail, fax and e-mail addresses noted above.

Notice. No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

∞ The text paper used in this publication meets the minimum requirements of American National Standard for Information Sciences–Permanence of Paper for Printed Library Materials, ANSI Z39.48-1984.

Publishing, Advertising, and Subscription Office

Elsevier Science Inc., 655 Avenue of the Americas, New York, NY 10010-5107, USA.

Please direct inquiries regarding advertising in this journal to:

The Americas: Jay Allan Feinman, Advertising Sales Dept., Elsevier Science Inc., 655 Avenue of the Americas, New York, NY 10010-5107. Tel: (212) 633-3689. Fax: (212) 633-3820. E-Mail: j.feinman@elsevier.com.

Rest of world (excluding Japan): Advertising Department, Elsevier Science, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, United Kingdom. Tel: (+44) (0) 1865 843565. Fax: (44) (0) 1865 843976. E-mail: media@elsevier.co.uk.

Japan: Advertising Department, Elsevier Science K.K. Tel: (81) (3) 5561 5033. Fax: (81) (3) 5561 5047.

Reprints of any article in this journal are available for purchase in quantities of 100 or more. Please contact Anne Rosenthal, Commercial Reprints Dept., Elsevier Science Inc., 655 Avenue of the Americas, New York, NY 10010-5107. Tel: (212) 633-3813. Fax: (212) 633-3820. E-Mail: a.rosenthal@elsevier.com.

Frequency: Published monthly.

Subscription Rates (2002)

Institutional price: USD 2,920.00; JPY 346,800; EUR 2,611. Prices include postage and are subject to change without notice. Any inquiry relating to subscription should sent to:

New York: Elsevier Science, PO Box 945, New York, NY 10159-0945, USA; phone: (+1) (212) 633 3730 [toll free number for North American customers: 1-888 4ES-INFO (437-4636)]; fax: (+1) (212) 633 3680; e-mail: usinfo-f@elsevier.com.

Amsterdam: Elsevier Science, PO Box 211, 1000 AE Amsterdam, The Netherlands; phone: (+31) 20 4853757; fax: (+31) 20 4853432; e-mail: nlinfo-f@elsevier.nl.

Tokyo: Elsevier Science, 9-15 Higashi-Azabu 1-chome, Minato-ku, Tokyo 106-0044, Japan; phone: (+81) (3) 5561 5033; fax: (+81) (3) 5561 5047; e-mail: info@elsevier.co.jp.

Singapore: Elsevier Science, No. 1 Temasek Avenue, #17-01 Millenia Tower, Singapore 039192; phone: (+65) 434 3727; fax: (+65) 337 2230; e-mail: asiainfo@elsevier.com.sg.

Rio de Janeiro: Elsevier Science, Rua Sete de Setembro 111/16 Andar, 20050-002 Centro, Rio de Janeiro-RJ, Brazil; phone: (+55) (21) 509 5340; fax: (+55) (21) 507 1991; e-mail: elsevier@campus.com.br. [Note (Latin America): for orders, claims and help desk information, please contact the Regional Sales Office in New York as listed above]

Periodicals postage paid at New York, NY. Postmaster send address corrections to *General Pharmacology*, c/o Elsevier Science Inc., 655 Avenue of the Americas, New York, NY 10010-5107, USA.

Copyright © 2002 Elsevier Science Inc. All rights reserved.

ELSEVIER

General Pharmacology 36-37 (2002) v

General Pharmacology
The Vascular System

Publisher's note

These two Index Volumes of the journal *General Pharmacology — The Vascular System* are the last two of the journal with its present title and are meant to give the reader an overview of what has been published in *General Pharmacology* during the period of its existence.

Because of developments in pharmacology and the focus of the papers received by the journal during the past few years, the Editor-in-Chief and the Publisher have after careful deliberation decided to change the title of the journal into **Vascular Pharmacology**, so as to better reflect the actual contents of the journal.

We trust that our readership will continue to submit their valued work to the journal and that we will thus be able to continue to provide you with the interesting, high-quality content the journal is known for.

To start the new life of the journal, a number of thematic issues reflecting the new focus of the journal have been organized. Please consult the journal's website: *http://www.elsevier.com/locate/vph*.

PII: S0306-3623(02)00132-5

The index and/or table of contents has been removed and photographed separately within this volume year.

For roll film users, this information for the current volume year is at the beginning of the microfilm. For a prior year volume, this information is at the end of the microfilm.

For microfiche users, the index and/or contents is contained on a separate fiche.

General Pharmacology
The Vascular System

Information for Contributors

1. Paper should be submitted to the Editor-in-Chief:

   Dr. John D. Catravas
   Vascular Biology Center
   Medical College of Georgia
   Augusta, GA 30912-2500 USA

2. Submission of a paper implies that it has not previously been published, that it is not under consideration of publication elsewhere, and that, if accepted for publication, it will not be published elsewhere in the same form without the written permission of the Editor-in-Chief. Articles and illustrations become the property of the journal.
3. Manuscripts and illustrations should be submitted in quadruplicate, and the author should retain at least 1 copy.
4. Manuscripts should be typewritten, with double spacing and wide margins. Authors are requested to keep their communications as concise as possible. Footnotes should be avoided and italics should not be used for emphasis. A short title (running-head) of not more than 30 characters should be supplied.

   Authors are required to submit a 3.5-inch HD/DD computer disk to the editorial office. Please observe the following criteria:

   a. Send only hard copy when first submitting your paper.
   b. When your paper has been refereed, revised if necessary, and accepted, send a disk containing the final version with the final hard copy, make sure that the disk and the hard copy match exactly (otherwise the diskette version will prevail).
   c. Specify what software was used, including which release, e.g., WordPerfect 6.0a.
   d. Specify what computer was used (IBM compatible PC, Apple Macintosh, etc.).
   e. The article file should include all textual material (text, references, tables, figure captions, etc.) and separate illustration files, if available.
   f. The file should follow the general instructions on style/arrangement and, in particular, the reference style of this journal as given in the Information for Contributors.
   g. The file should be single spaced and should use the wrap-around end-of-line feature, i.e., *returns at the end of paragraphs only*. Place two returns after every element such as title, headings, paragraphs, figure and table call-outs.
   h. Keep a back-up disk for reference and safety.

5. In general, the typescript should follow the conventional form: title, author's name and full address, abstract, introduction, materials and methods, results, discussion, conclusion, summary, references, tables, legends to figures and figures. The address of the author to whom correspondence and proofs should be sent must be given on the first page. Provide telephone and FAX numbers, and E-mail address, if available, of the corresponding author with the manuscript, for use by the publisher.
6. *The Abstract*. This should be very short, between 100 and 200 words, and should contain numerical and factual data only. Together with the title it should serve to make the precise significance of the paper clear to the non-specialist reader.
7. *Illustrations*. All necessary illustrations should accompany the manuscript, but should not be inserted in the text. All photographs, graphs, and diagrams should be numbered consecutively in arabic numbers in the order in which they are referred to in the text.

   Glossy photographs or positive prints (not X-ray negatives or slides) should be sent unmounted, wherever possible, and should be restricted to the minimum necessary.

   Charts, graphs, or diagrams should be printed in dark black ink on good-quality white paper. Lettering to appear on the illustration should be given in full and should be of sufficient size to withstand considerable reduction, where necessary.

   Illustrations should not be larger than 10×8 in. or they may be damaged in the post. On the back of each illustration should be indicated the author's name, the figure number, and the top of the illustration, where this is not clear.

   The following symbols should be used on line drawings as they are readily available to the printer:

   ○ ● + × □ ■ △ ▲ ▽ ▼

   Legends to figures should be typed on a separate sheet and not on the back of or below the original, and should provide sufficient data to make the illustration comprehensible without reference to the text. All abbreviations and labels used in the figure must be defined in the legend.
8. *References*. The Harvard system is followed. References should be detailed in the following order: authors' names and initials, date of publication, the title of the article, the name of the journal as abbreviated in the *World List of Scientific Periodicals* (4th edn, 1963) the volume, and the first and last pages of the article, e.g.

   Calcutt, C.R., 1976. The role of histamine in the brain. Gen Pharmac 7, 15–25.

   For books, the author's name, date of publication, title, edition, publisher and location, and page reference should be given, e.g.:

   Mickleson, M.J., Zeimat, E.V., 1973. Drug metabolism in the vole, 3rd edn (Vol. 1). Pergamon Press, Oxford, pp. 61–77.

   For a chapter in a book, author's name, date of publication, title of chapter, editors, title of book, publisher and location, and page reference should be given, e.g.:

   Glover, W.P., 1984. Sensitivity of vascular smooth muscle. In: Garlick, D. (Ed.), Progress in microcirculation. Committee in Postgraduate Medical Education, Sydney, pp. 287–295.

   In the text references should be given as: Smith (1964) or (Smith, 1964), or (Smith and Jones, 1998). In the case of three or more authors, et al. should be used throughout, i.e., Smith et al. (1964). If works published by the same author(s) in the same year are cited, they should be distinguished by the letters a, b, c, etc.
9. Only standard abbreviations should be used. Where specialized abbreviations are used the name should be given in full in the first instance with the abbreviation indicated in parentheses.
10. Please supply the names and addresses (including telephone and FAX numbers, and E-mail address if available) of at least three researchers of recognized experience who may be considered as referees.
11. Page proofs will be sent to the corresponding author for checking. **Corrections to the proofs must be restricted to printer's errors.** Any substantial alterations other than these may be charged to the author.

    Authors are requested to return their corrected proofs as quickly as possible (via overnight mail or some other trackable method) to facilitate rapid publication. Please note that **authors are urged to check their proofs carefully before return, since the inclusion of late corrections cannot be guaranteed.**
12. Offprints and copies of the issue (at a specially reduced rate) can be ordered on the offprint order form accompanying the proofs.
13. The original manuscript and diagrams will be discarded one month after publication unless the publisher is requested to return original material to the authors.

0306-3623(200101/12)36/37;1-0


1.0
2.8
2.5
3.2
2.2
3.6
4.0
2.0
1.1
1.8
1.25
1.4
1.6